introductioN

From the CEO

“I have personal experience on how devastating a brain disorder that changes your behavior and personality can be. My mother, who died in 2014, suffered from Alzheimer’s. My personal commitment is to develop a cure for Alzheimer’s disease, no matter what this may cost. There is no plan B.”
- Nikolaos Tezapsidis
CEO, Neurotez

problem

Alzheimer’s disease affects about 6 million Americans and 50 million patients worldwide.

Current medications provide limited relief.

Many of our competitors are focusing on removing either Abeta or tau deposits from the brain where they form plaques and tangles. None of these efforts have generated any effective drug for the last 18 years since the first anti-Abeta trial started.

The idea that Abeta and plaque do not cause Alzheimer’s is gaining momentum in the research community; we were determined to look for a different solution prior to the formation of the plaques.

solution

Our novel approach focuses on Leptin, a naturally occurring human hormone associated with various metabolic effects, which has a large number of receptors in memory centers of the brain.

Hippocampus (in red) responsible for memory formation, cognition and executive function is severely affected by the disease. This region is rich in Leptin receptors.

This protein is often present at decreased levels in patients suffering from Alzheimer’s disease, and cognitive deterioration in AD patients correlates strongly with a decline in circulating Leptin levels.

We are developing Memtin™ to treat Leptin deficiency in Alzheimer’s patients.

This Leptin product may act as a novel hormone replacement therapy for Alzheimer’s disease (AD) and/or as a preventative for those who are at risk.

"Alzheimer's Drugs Market Size is projected to reach US$~9.67 billion by 2031."
---

market

Alzheimer's is the fifth-leading cause of death among those aged 65 and older and is also a leading cause of disability and poor health. An estimated 5.8 million Americans aged 65 and older were living with Alzheimer's dementia in 2020. 80% of this population was aged 75 or older. This number is expected to increase to 13.5 million by 2050. Among people of age 70, 61% of those with Alzheimer's dementia are expected to die before the age of 80 compared with 30% of people without Alzheimer's. The rising prevalence of Alzheimer's disease has increased the demand for the treatment, which in turn is expected to boost the market growth. (2020 Alzheimer's disease facts and figures)

2020 Alzheimer's disease facts and figures

success to date

  • ​​​​​InvestAcure Coin Award 2019
    InvestAcure honored Nik Tezapsidis with the Cure Coin Award for his work in the development of Memtin, a novel recombinant human Leptin product, used as a hormone replacement therapy, showing potential in both slowing down and preventing Alzheimer’s.
  • 2010 Incubator Company to Watch
    Neurotez was chosen as a 2010 Incubator Company to Watch at the NJTC Gala Awards

Previous Funding Total = $4.8M:

  • National Institutes of Health
  • IRS Qualifying Therapeutic Discovery Project Grant
  • New Jersey Commission of Science and Technology
  • Previous crowdfunding raise of $300k

press

  • The National Herald
  • Ellines.com
    Aims in finding the cure for Alzheimer’s disease
  • Tapinto.net
    Resident Working to Find a Cure for Alzheimer's Disease Invites Public to “Have Fun Do Good" Event on Nov. 13

team

Operating Team

An impressive group of exceptional individuals with deep experience and success in their respective fields in Academia (100s of publications in Alzheimer’s) and Pharmaceutical Industry have been working together for a number of years to achieve our mission.

Nikolaos Tezapsidis
President and CEO, Founder of Neurotez Inc.
PhD in Biochemistry at the University of Sussex, UK 18+ years of biomedical research, 50 publications, 23 issued patents/patent applications. Two awards from the Alzheimer’s Association, Fellowship from Wellcome Trust and the Science and Engineering Council, UK

Wes Ashford
Chief Medical Officer
MD and PhD in Neuroscience from UCLA, 100+ publications on Alzheimer’s disease, Senior Research Scientist at the Stanford/VA Aging Clinical Research Center and Alzheimer’s Center
Hamish McArthur
Chief Manufacturing Officer
PhD in Microbial Biochemistry at University of Cambridge, 33 years of drug development experience at Pfizer, 50+ publications and patents

Jukka Karjalainen
COO
25+ years of pharma experience in US, Canada, and Europe, authored 55 original publications in top-rated international medical journals, Member of International Science Advisory Board

Jane Johnston
VP Operations
PhD in Biochemistry from Imperial College, 18+ years of research experience in neural repair and cellular imaging, Principal Investigator for the University of Medicine and Dentistry of New Jersey and Albert Einstein College of Medicine

Bob Oliver
Director
MBA in Marketing from the Haub School of Business at Saint Joseph’s University, President and CEO of Otsuka America Pharmaceutical, Inc., VP and Global Business Manager for Oncology at Wyeth
James Harris
Acting CFO
MBA in Finance from Long Island University, CEO of Healthcare Economics LLC VP at Dragon Pharmaceuticals, Inc.
Thomas J. Humphries
Director
36 years of experience in Pharma and Biotech, 225+ papers published, retired as a Colonel after 26 years in the Navy and Airforce

Use of Proceeds


If the offering's maximum amount of $500,000 is raised:

UseValue% of Proceeds
Compensation for managers$120,00024.0%
Research and Development$230,50046.1%
Marketing$60,00012.0%
Legal$60,00012.0%
Taxes and Fees$5,0001.0%
Intermediary fees$24,5004.9%

Terms

This is an offering of Common Stock, under registration exemption 4(a)(6), in Neurotez Inc.. This offering must raise at least $10,000 by November 1, 2022 at 10:00pm ET. If this offering doesn’t reach its target, then your money will be refunded. Neurotez Inc. may issue additional securities to raise up to $500,000, the offering’s maximum.

If the offering is successful at raising the maximum amount, then the company’s implied valuation after the offering (sometimes called its post-money valuation) will be:

11,443,057 shares
×
$4 per share
$45,772,228implied valuation

Pitch Deck

Financials

These financial statements have been reviewed by an independent Certified Public Accountant.

SEC Filings

The Offering Statement is a formal description of the company and this transaction. It’s filed with the SEC to comply with the requirements of exemption 4(a)(6) of the Securities Act of 1933.

We’re also required to share links to each of the SEC filings related to this offering with investors.

Understand the Risks

Be sure to understand the risks of this type of investment. No regulatory body (not the SEC, not any state regulator) has passed upon the merits of or given its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials or information posted herein. That’s typical for Regulation CF offerings like this one.

Neither Netcapital nor any of its directors, officers, employees, representatives, affiliates, or agents shall have any liability whatsoever arising from any error or incompleteness of fact or opinion in, or lack of care in the preparation or publication of, the materials and communication herein or the terms or valuation of any securities offering.

The information contained herein includes forward-looking statements. These statements relate to future events or to future financial performance, and involve known and unknown risks, uncertainties, and other factors, that may cause actual results to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the company’s control and which could, and likely will, materially affect actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects the current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. No obligation exists to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

More Info

Updates

  • Sep 12, 2022
  • Sep 9, 2022
    We are very delighted to announce the addition...

    We are very delighted to announce the addition of Royston G King to our advisory Board….(https://lnkd.in/eYD5DYi7) Royston G King is a self-made & world-renowned multi-millionaire award-winning 8-figure serial entrepreneur, multiple best-selling author, celebrity socialite media personality, most coveted TEDx & keynote speaker, & world’s leading preeminent philanthropist. Partner & advisor to celebrities, billionaires, royal family brands, billion-dollar brands, public-listed companies, New York Times best-selling authors, social media verified (actors, pro athletes, musicians, entrepreneurs, personal brand influencers, etc.), Fortune500, Forbes 1000, Inc5000, & the world’s biggest brands Investor & board of advisor to 100+ companies across hundreds of all types of industries & 6 continents. All with enterprise value surpassing USD $1+ billion.

  • Sep 1, 2022
    Primary offering of 125,000 shares at $4
  • Sep 1, 2022

Ask a Question

Proofread your comment before submitting: once it's posted, you can’t edit or delete it. For the fastest help with the web site, email help@netcapital.com instead of commenting.

Looking to raise capital?
We can help turn your friends, family and customers into investors.

Learn more

Interested in more investment opportunities?
Browse all offerings currently available.

See more